

New Clicked Full Agonists of the Estrogen Receptor β

Sebastian Demkowicz,^{a, b} Kamila Filipiak,^{a, c} Maciej Maslyk,^{a, c} Jakub Ciepielski,^{a, d} Sonia de Pascual-Teresa,^e Sonsoles Martín-Santamaría,^a Beatriz de Pascual-Teresa,^{*a} Ana Ramos.^{*a}

Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

A click chemistry approach was used to synthesize a series of 1,4-diaryl-substituted 1,2,3-triazoles designed to behave as estrogen receptor ligands. We studied their affinities for both receptors α and β , their agonist activities in a cell-based luciferase reporter assay and their effect on the proliferation of the hormone dependent MCF-7 cell line. We found two compounds (**3a** and **3c**) that behave as selective full agonists for ER β at a 20 μ M concentration, and one of them (**3c**) deprived of proliferative effect on MCF-7 cells.

Introduction


The estrogen receptor (ER) is a member of the nuclear receptor gene family binding the steroid hormone estradiol.¹ Two subtypes are known of ER, designated ER α and ER β . Both ER subtypes have overlapping but also unique roles in estrogen-dependent action and are important targets in pharmaceutical industry. Additionally, ER α and ER β have different transcriptional activities in certain ligand, cell-type, and promoter contexts.

The low expression level of ER β in reproductive tissues such as uterus, suggests that a selective ER β agonist may maintain the beneficial effects of estrogen, without the increased risk of breast and endometrial cancer. A number of selective ligands have been already identified.² ER β selective agonist ERB-041 (226-fold selective for β) has been used to demonstrate that this receptor may be a useful target for certain inflammatory processes.³ Other nonsteroidal scaffolds which have been developed as ER β ligands are diarylpropanenitriles (DPN),⁴ 2-phenylnaphthalenes (WAY-202196),^{2, 5} and aryll-2H-indazoles.⁶ We have described a series of benzonaphthofuran and naphthothiophene based ligands which behave as ER β agonists and ER α antagonists,⁷ and present an interesting antitumor activity against two pancreatic cell lines.⁸ Introduction of a basic side chain in these scaffolds has led to full antagonists of ER β , with potency in the low micromolar concentration in a cell-based luciferase reporter assay, and completely devoid of activity against the ER α at the same concentration range.⁹

Click chemistry has had a profound effect on the design and development of novel compounds for therapeutic applications.¹⁰ In particular, the Copper-Catalyzed reaction between an Azide and an Alkyne (CuAAC) has been widely used in fragment-based drug design, and target-guided synthesis (*in situ* click

chemistry).¹¹

Tron and coworkers¹² used CuAAC click chemistry to obtain a series of 1,4-diaryl-substituted 1,2,3-triazoles **1** (Fig. 1) and evaluated their effect on the proliferation of the hormone dependent MCF-7 cell line. The only active compound promoted proliferation at a 100 pM concentration and possessed the two hydroxy groups in *meta* position. This compound was capable of promoting transcriptional activation in HeLa cells expressing higher levels of ER β than ER α at low concentrations. These data suggest ER- β selectivity, but further studies on the affinity and transcriptional response on both receptors are required to establish the subtype selectivity of this type of compounds.



benzonaphthofuran (thiophene) based ligands

Fig. 1 Chemical structures of some known ER β -selective ligands

In the search of new and selective ligands of both estrogen receptor isoforms, we were interested in the observation of the authors that the introduction of a triazole ring is compatible with binding to the estrogen receptor, and the possibility to apply this efficient synthetic procedure to obtain analogues with additional substituents on the aromatic rings that could favor the interactions with one of the receptor subtypes.

Thus, we have synthesized two series of 1,4-bis(hydroxyphenyl)-1*H*-1,2,3-triazoles **2a-f** and **3a-f** (Fig. 2), where methyl, trifluoromethyl, fluoro, carboxy and methoxycarbonyl groups have been introduced in *ortho* and *meta* positions of one of the aromatic rings. We have evaluated the ER α and ER β binding affinities of the synthesized compounds and studied the transcriptional activation and proliferative activity in MCF-7 breast cancer line of the most interesting of these.

The best binders were compounds **2a** and **3a**, showing IC₅₀ of 8.4 and 8.00 μ M, respectively in ER α and lower binding affinity to ER β . Compound **3a** emerged as a full ER β agonist at 20 μ M, while its effect on ER α was negligible at the same concentration. This compound stimulated proliferation of MCF-7 cells with maximal proliferation at 10 μ M. Interestingly, analogue **3c** behaved as well as a full ER β agonist at 20 μ M, but was deprived of proliferative activity.




Fig.2 Structure of the synthesized 1,4-diaryl-substituted 1,2,3-triazoles

Results and discussion

Molecular Modelling

Preliminary docking studies were carried out in order to assess the capability of the designed compounds to interact with the ligand binding domain (LBD) of both ERs. Several crystallographic structures of the two receptor subtypes in complex with several ligands have been considered: ER α in complex with estradiol (PDB 1A52), raloxifene (PDB 1ERR), genistein (PDB 1X7R), WAY-244 (PDB 1X7E), and 4-hydroxytamoxifen (PDB 3ERT), and ER β in complex with genistein (PDB 1X7J), THC (PDB 1L2J), WAY-202196 (PDB 1YYE), and 4-hydroxytamoxifen (PDB 2FSZ).

All the candidates to be synthesized (**2** and **3**) were able to bind ERs, at least theoretically.

Regarding predicted binding energies, these were more favourable in the case of ER β -ligand complexes, as most of the ligands led to values within the highest energy range (from -7.3 to -9.5 kcal/mol) together with estradiol-like poses. However, in the case of ER α , only two compounds, **2a** and **3a**, led to the best values in ER α (-7.9 kcal/mol), although with different docked

poses: **2a** presents a pose different to that for estradiol, while **3a** establishes interactions similar to those found for estradiol, as will be discussed below.

Regarding the binding mode, the analysis of the docking studies showed that all compounds could adopt estradiol-like poses in ER β , while in ER α no estradiol-like poses were found or they did not show proper binding. Compounds **3a** and **3d**, were an exception, because they were the only ligands exhibiting estradiol-like poses when docked inside ER α (predicted binding energies of -7.9 and -6.8 kcal/mol, respectively).

Overall, these results may point to a preference for ER β binding, with the exception of compounds **2a** and **3a**, which may present binding abilities for both receptors.

When studying ligand-receptor interactions at atomic detail, it can be observed that compound **3a** establishes hydrogen bonds between the OH-1 group and Glu305-Arg346, and the OH-3'' group with His475 (ER β numbering), in an estradiol-like fashion in both ER subtypes. Additionally, the CF₃ group is hosted in a hydrophobic cavity delimited by Leu339, Met340, Leu343, and Leu380 (in ER α : Leu387, Met388, Leu391, and Leu428). In the case of **3d**, which also establishes estradiol-like binding modes in both receptors, the presence of the CH₃ group in this position led to a decrease of 1.1 kcal/mol in the docked binding energy, indicating the role of the CF₃ group in the binding (see ESI). The CF₃ group is also present in **2a**. In ER β , docking studies for this compound led to an estradiol-like binding pose with the opposite orientation to that found for **3a**. So, hydrogen bonds were identified between OH-1 and His-475; and between OH-4'' and Glu305-Arg346. The CF₃ is accommodated in the vicinity to the previously mentioned hydrophobic cavity, contacting Leu380, Ile376, and Phe377 side chains (Fig. 3). In the case of ER α , this compound is predicted to bind in a non estradiol-like pose. These results suggest that the presence of a lipophilic R¹ group could favour the binding by the establishment of hydrophobic interactions with the cavity delimited by Leu339, Met340, Leu343, Ile376, Leu380 and Phe377 side chains (ER β numbering), and that scaffold **3** is more suitable for anchoring the receptor (specially ER β).






Fig. 3 Docked binding modes obtained for compounds **2a** and **3a** in ER β .

Chemistry

As a result of the previous theoretical study, we decided to synthesize compounds **2** and **3**. The detailed synthesis of the azide fragment is shown in Scheme 1. Some of the amines used



Scheme 1. Synthesis of ligands **2** and **3**. (a) H₂, Pd/C for **4a**, Sn/HCl for **4b** and **4c**; (b) 1 eq. TIPSCl/Et₃N for **5a-d**, 2 eq. TIPSCl/Et₃N for **5e-f**; (c) *t*-BuONO/TMSN₃; (d) TBFA, CuSO₄·5H₂O, sodium ascorbate, DMF; (f) MeOH, H₂SO₄.

(**4d-f**) are commercially available, and some had to be synthesized (**4a-c**) by Sn/HCl reduction of the corresponding nitrocompounds. After protection of the hydroxyl group (together with the carboxylic groups in the case of **4e** and **4f**), the TIPS-protected derivatives were transformed into azides **6** by reaction with *tert*-butyl nitrite and azidotrimethylsilane.

These azides were coupled to 3-ethynylphenol and 4-((trimethylsilyl)ethynyl)phenol. The former is commercially available, and the latter was obtained by Sonogashira coupling between the commercially available 4-iodophenol and trimethylsilyl acetylene.

For the CuAAC reaction, we used CuSO₄ (0.1 eq.) and ascorbic

acid (0.2 eq) in the presence of tetrabutylammonium fluoride to bring about the deprotection of 4-((trimethylsilyl)ethynyl)phenol in the reaction mixture and the deprotection of the final triazoles.

We have chosen this synthetic pathway, involving the use of protective groups, because, in our first attempt to carry out the click reaction starting from unprotected azides, we observed a low solubility of the reactants in the reaction medium, and the formation of a complex mixture of compounds by TLC and ¹H-NMR analysis of the crude reaction.

Finally, acids **2e,f** and **3f** were transformed into the corresponding methyl esters **2g,h** and **3h** by reaction with MeOH in the presence of H₂SO₄.

Estrogen Receptor Binding Assays.

The affinity for ERα and ERβ of compounds **2** and **3** were determined in an in vitro competitive binding assay, following a reported method,¹³ with some modifications. All compounds were tested at 10 μM and only compounds **2a**, **2e**, **3a** and **3d** presented enough affinity at this concentration to determine the IC₅₀ at least in one of the receptors. Table 1 shows a summary of the results.

Table 1 Affinities^a of compounds **2** and **3** (IC₅₀) and % of [³H]-estradiol binding to ERα and β at 10 μM.

| ligand | IC ₅₀ ERα (μM) | IC ₅₀ ERβ (μM) | β/α ratio | 10 μM ERα | 10 μM ERβ |
|-----------|---------------------------------|---------------------------------|-----------|--------------|--------------|
| 2a | 8.4 | 22.6 | 2.6 | 47 | 75.3 |
| 2b | NA | NA | - | 98.5 | 100 |
| 2c | NA | NA | - | 100 | 100 |
| 2d | NA | NA | - | 76.9 | 87.3 |
| 2e | 14.5 | 130.0 | 8.9 | 60.9 | 79.7 |
| 2f | NA | NA | - | 94.8 | 100 |
| 2g | NA | NA | - | 83.9 | 94.4 |
| 2h | NA | NA | - | 98.6 | 100 |
| 3a | 8.00 | >100 | - | 50.7 | 100 |
| 3b | NA | NA | - | 100 | 100 |
| 3c | NA | NA | - | 100 | 100 |
| 3d | 61.4 | >100 | - | 72.5 | 100 |
| 3e | NA | NA | - | 100 | 100 |
| 3f | NA | NA | - | 97.8 | 100 |
| 3h | NA | NA | - | 78.3 | 100 |

^a Values are an average of at least 2 experiments with typical standard errors below 15%. NA - not achieved

^b The percentage of specific binding of [2,4,6,7,16,17-³H]-estradiol to ER.

⁴⁵

Transcription Assays.

To characterize the agonist/antagonist profile we first submitted three compounds (**2a**, **2e**, and **3a**) with the highest binding affinity.

They were assayed for transcriptional activity through both receptor subtypes, with estradiol as a reference. Reporter gene assays were conducted in mammalian cells containing either ERα or ERβ-responsive luciferase reporter gene. The luciferase gene expression appears when ligand-bound ER undergoes nuclear translocation, DNA binding, assembling of the co-activators and other factors which are necessary to obtain a functional

transcription complex, in which target gene is expressed. The readout from those reporter cells fulfils similar interaction demands to those which can be observed in vivo. In the reporter gene assays on cells treated with saturating concentrations of estradiol, ER β showed a maximal activity which was 62% lower than the maximal activity observed on ER α . This observation is in agreement with previous published results.¹⁴

Compounds **2a** and **3a** showed agonistic effects in ER β (Fig. 4). Thus, compound **2a** induced a significant increase in luciferase activity (414 \pm 8,46 % of control) at 10 μ M, and compound **3a** showed a very high efficacy at 20 μ M (633 \pm 67,8 of control), which is comparable to the maximum response of estradiol (694,38 \pm 6,21 of control at 4 nM). Compound **2e** induced some increase in transcriptional activity but it was not concentration-dependent.




Fig. 4 Transcriptional activation of ER β by estradiol (4 nM) and compounds: **2a**, **2e**, **3a** and **3c**.

In the case of ER α (Fig. 5), compound **2a** was able to activate the receptor with the maximum activity at 20 μ M (859,56% of control) in comparison to the maximum response of estradiol in this receptor (1689,06 \pm 74,17 at 100 nM). These results suggest that **2a** behaves as an agonist for both receptors with similar efficacy.




Fig. 5 Transcriptional activation of ER α by estradiol (100nM) and compounds **2a**, **2e**, **3a** and **3c**

More interestingly, only a slight activity on ER α was observed in the case of compound **3a** at 20 μ M (320,42 \pm 14,74 of control) in comparison to 1689,06 \pm 74,17 for 100 nM of estradiol. This result

demonstrates that **3a** is selective in its transcriptional activity, behaving as a full agonist for ER β at 20 μ M, while being a weak agonist for ER α at the same concentration. It is of great interest to detect non-steroidal molecules that display agonistic or antagonistic properties on the ERs in a specific manner.

It should be noted that there is no correlation between binding affinity and transcriptional potency for this compound. This lack of correlation has been observed in other cases,¹⁵ and could be explained by differences in the mode of binding between the ligands, the ERs and various cellular coregulators, which could modulate the final ligand response in the transcriptional assay.

Finally, no transcriptional effect was present on ER α at the tested concentrations in the case of **2e**. This compound could be classified as a selective partial agonist of ER β . No antagonistic activity was observed for all tested compounds.

Effect on the proliferation of a MCF-7 breast cancer cell line.

We determined the proliferative activity of all the synthesized compounds on the hormone dependent MCF-7 breast cancer line (Fig. 6 and Fig. 7).




Fig.6 Concentration response curves of proliferation of MCF-7 treated with the following compounds: **2a**(●), **2e**(▼), and **3a**(■), evaluated with crystal violet assay. Data are mean \pm SD of at least 5 determinants in 2 independent experiments.

Compound **3a** induced an increase in proliferation, displaying a bell-shape dose response curve, with maximal proliferation at 10 μ M (1529,15 \pm 99,6) of solvent control in comparison to 446,17 \pm 45,4 obtained for 1 pM estradiol. The other two ER binders **2a** and **2e** also increased proliferation but with lower efficacy with maximum at 10 μ M (581,59 \pm 33,12) and 50 μ M (483,35 \pm 39,81) for **2a** and **2e**, respectively.


This proliferative activity could be explained by its effect on the ER pathway, as we proved that these compounds behave as ER agonists.

The rest of compounds presented different profiles that did not correlate with their binding affinities (Fig. 7). Interestingly compound **3c** did not induce proliferation of MCF7 cells, what is in agreement with its lack of affinity for both receptors in the binding assay. However, taking into account the observed lack of correlation between the binding affinity and the functional

activity of the previously studied compounds (**2a**, **2e** and **3a**), we decided to study its transcriptional activation capability (Fig. 4 and Fig. 5). We found that **3c** behaved as a full agonist at 20 μ M, increasing luciferase activity ($634,1 \pm 30,8$ of control) in a similar extent than estradiol at 4 nM ($694,38 \pm 6,21$), while its activation of ER α ($455,2 \pm 14,2$ of control) was only 27% of control activity of estradiol ($1689,06 \pm 74,17$ at 100 nM) (Fig. 4 and Fig. 5)

Thus, **3c** is a full ER β agonist, without promoting the proliferation of MCF-7 cells, a biological profile which holds promise for the treatment of inflammatory diseases including rheumatoid arthritis, and cardiovascular and CNS conditions.¹⁴

a)



b)




Fig.7 Concentration response curves of proliferation of MCF-7 treated with the following compounds: a) **2b**(●), **2c**(▼), **2d**(■), **2f**(▲), **2g**(○), **2h**(□) and b) **3b**(○), **3c**(■), **3d**(●), **3e**(▼), **3f**(▲), **3h**(□). Data are mean \pm SD of at least 5 determinants in 2 independent experiments.

Conclusions

A series of *clicked* 1*H*-1,2,3-triazoles have been synthesized, and their affinity and transcriptional activation of both ER α and ER β have been determined by means of in vitro assays. This study has allowed us to detect two compounds (**3a** and **3c**) that behave as selective full agonists for ER β at 20 μ M, while its effect on ER α is considerably lower at the same concentration. These compounds could be useful to gain knowledge on the

physiological role of ER β . While **3a** induced the proliferation of MCF-7 cells, its analogue **3c** was completely inactive in this breast cancer cell line. This compound constitutes therefore, a new and promising candidate for the development of ER binding agents useful for the treatment of inflammatory, cardiovascular and CNS diseases, without promoting undesired proliferative effects on breast.

Experimental

General Methods. Melting points (uncorrected) were determined on a Stuart Scientific SMP3 apparatus. Infrared (IR) spectra were recorded with a Perkin-Elmer 1330 infrared spectrophotometer. 1 H and 13 C NMR were recorded on a Bruker 300-AC instrument. Chemical shifts (δ) are expressed in parts per million; coupling constants (*J*) are in Hertz. Mass spectra were run on a Bruker Esquire 3000 spectrometer. Thin-layer chromatography (TLC) was run on Merck silica gel 60 F-254 plates. Unless stated otherwise, starting materials used were high-grade commercial products. For all tested compounds > 95% purity was confirmed by HPLC/MS using a Esquire 3000 ion-trap mass spectrometer (Bruker-Daltronics, Bremen, Germany) coupled to an Agilent HPLC system type HP 1100. A LiChroCART Supersphere100 RP-18 column (125 x 2 mm; 4 μ m particle size) was used, eluting with H₂O + 0.1% TFA / MeOH + 0.1% TFA or Acetonitrile + 0.1% TFA. Acid **2f** was obtained in a complex mixture with other unknown compounds, and was not possible to isolate it pure. However it could be transformed into the corresponding methyl ester **2h**.

General method for the synthesis of amines 4a-c:

To a 100 ml round bottomed flask, containing a stirrer bar and a reflux condenser, tin (1.65 g, 14 mmol) and the corresponding phenol (10 mmol) were added. Then water (24 mL) followed by concentrated hydrochloric acid (9 mL) were added, and the solution was heated under reflux for 1.5 h. Then, the reaction mixture was cooled in an ice bath, a 5 M NaOH solution (20 mL) was added, and the aqueous solution was extracted with AcOEt (3 x 50 cm³) and the combined organic extracts were washed with saturated aqueous NaHCO₃ and brine, dried (MgSO₄) and concentrated to dryness to give the desired amine **4**

4-Amino-3-trifluoromethylphenol 4a. Yield 88%; 1 H NMR δ _H (300 MHz; DMSO) 4.88 (2H, s, NH₂), 6.68-6.80 (3H, m, ArH), 8.92 (1H, s, OH).

4-Amino-2-fluorophenol 4b. Yield 93%; 1 H NMR δ _H (300 MHz; CD₃OD) 6.25-6.32 (1H, m, ArH), 6.40 (1H, dd, *J* 12.1, 2.4), 6.59 (1H, dd, *J* 9.6 and 8.6); 13 C NMR δ _C (75.4 MHz, CD₃OD) 105.3 (*J*_{CF} 21Hz), 112.9 (*J*_{CF} 3Hz), 119.3 (*J*_{CF} 4Hz), 138.0 (*J*_{CF} 13Hz), 141.6 (*J*_{CF} 9Hz) and 153.4 (*J*_{CF} 238Hz)

4-Amino-2-methylphenol 4c. Yield 90%; 1 H NMR δ _H (300 MHz; CD₃OD) 2.01 (3H, s, CH₃), 6.34 (1H, dd, *J* 8.1 and 2.3, ArH), 6.41-6.48 (2H, m, ArH); 13 C NMR δ _C (75.4 MHz, CD₃OD) 16.76, 116.20, 116.77, 120.68, 126.64, 140.40 and 149.90.

General method for the synthesis of the TIPS-protected compounds 5a-d:

To a solution of the corresponding phenol (2.83 mmol) in dry DMF (2 mL) was added a solution of triisopropylsilyl chloride (0.655 g, 3.40 mmol) and triethylamine (0.315 g, 3.11 mmol) in dry DMF (1 mL) under N₂, and the mixture was stirred at RT for 24 hours. The solution was filtered and the solvent was evaporated. The resulting residue was purified by column chromatography using hexane/AcOEt (15:1) as eluent to give the desired product.

2-(Trifluoromethyl)-4-((triisopropylsilyloxy)aniline 5a. Yield 87%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.08 (9H, d, *J* 7.3, CH₃), 1.12 (9H, d, *J* 7.3, 2CH₃), 1.12-1.27 (3H, m, 3CH), 1.28-1.45 (3H, m, 3CH), 2.80-3.70 (2H, brs, NH₂), 6.54 (1H, d, *J* 8.7, ArH), 6.77 (1H, dd, *J* 8.7 and 2.7, ArH), 6.88 (1H, d, *J* 2.7, ArH).

3-Fluoro-4-((triisopropylsilyloxy)aniline 5b. Yield 80%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.00 (18H, d, *J* 6.9, 6CH₃), 1.12-1.35 (3H, m, 3CH), 3.37 (2H, brs, NH₂), 6.20-6.25 (1H, m, ArH), 6.32 (1H, dd, *J* 12.1, 2.8, ArH), 6.66 (1H, t, *J* 8.9, ArH).

3-Methyl-4-((triisopropylsilyloxy)aniline 5c. Yield 82%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.01 (18H, d, *J* 7.0, 6CH₃), 1.10-1.21 (3H, m, 3CH), 2.09 (3H, s, CH₃Ar), 3.10-3.40 (2H, brs, NH₂), 6.29 (1H, dd, *J* 8.3, 2.9, ArH), 6.42 (1H, d, *J* 2.9, ArH), 6.50 (1H, d, *J* 8.3, ArH).

2-Methyl-4-((triisopropylsilyloxy)aniline 5d. Yield 84%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.08 (9H, d, *J* 7.3, 3CH₃), 1.12 (9H, d, *J* 7.3, 3CH₃), 1.12-1.27 (3H, m, 3CH), 1.28-1.45 (3H, m, 3CH), 2.05 (3H, s, CH₃), 2.60-3.40 (2H, brs, NH₂), 6.46 (1H, d, *J* 8.3, ArH), 6.49 (1H, dd, *J* 8.3, 2.6, ArH), 6.55 (1H, d, *J* 2.6, ArH).

General method for the synthesis of the TIPS-protected compounds 5e and 5f:

To a solution of the corresponding acid (2.35 mmol) in dry DMF (2 mL) was added a solution of triisopropylsilyl chloride (1 g, 5.19 mmol) and triethylamine (0.500 g, 4.95 mmol) in dry DMF (1 mL) under N₂, and the mixture was stirred at RT for 24 hours. The solution was filtered and the solvent was evaporated. The resulting residue was purified by column chromatography using hexane/AcOEt (15:1) as eluent to give the desired product.

Triisopropylsilyl 2-amino-5-((triisopropylsilyloxy)benzoate 5e. Yield 94%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.08 (18H, d, *J* 7.3, 3CH₃), 1.12 (18H, d, *J* 7.3, 3CH₃), 1.12-1.27 (3H, m, 3CH), 1.28-1.45 (3H, m, 3CH), 5.00-5.85 (2H, brs, NH₂), 6.56 (1H, d, *J* 8.7, ArH), 6.89 (1H, dd, *J* 8.8 and 2.9, ArH), 7.43 (1H, d, *J* 2.9, ArH).

Triisopropylsilyl 5-amino-2-((triisopropylsilyloxy)benzoate 5f. Yield 86%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.00 (18H, d, *J* 7.3, 6CH₃), 1.03 (18H, d, *J* 7.3, 3CH₃), 1.12-1.38 (6H, m, 6CH), 2.55-3.00 (2H, br s, NH₂), 6.56-6.67 (2H, m, ArH), 7.02 (1H, d, *J* 2.1, ArH).

General method for the synthesis of azides.

To an ice cooled solution the corresponding compound 6a-f (1 g, 2.15 mmol) in CH₃CN (5mL), was added dropwise *t*-BuONO (0.332 g, 381 μL, 3.22 mmol) followed by TMSN₃ (0.301 g, 341 μL, 2.57 mmol) and the solution was stirred at room temperature for 4 h. After concentrating under vacuum, the crude product was purified by silica gel chromatography (hexane) to give the desired

product.

(4-Azido-3-(trifluoromethyl)phenoxy)triisopropylsilane 6a. Yield 67%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.01 (18H, d, *J* 7.3, CH₃ iPr), 1.10-1.21 (1H, m, CH iPr), 7.00 (1H, dd, *J* 8.6, 2.6, ArH), 7.05-7.09 (2H, m, ArH).

(4-Azido-2-fluorophenoxy)triisopropylsilane 6b. Yield 71%, oil

¹H NMR δ_H (300 MHz; CDCl₃) 1.00 (18H, d, *J* 6.9, 6CH₃), 1.09-1.28 (3H, m, 3CH), 6.55-6.63 (1H, m, ArH), 6.67 (1H, dd, *J* 11.1 and 2.6, ArH), 6.84 (1H, t, *J* 8.9, ArH); ¹³C NMR δ_c (75.4 MHz, CDCl₃) 11.6, 16.7, 106.6 (*J*_{CF} 22Hz), 113.5 (*J*_{CF} 3Hz), 121.4 (*J*_{CF} 3Hz), 132.1 (*J*_{CF} 9Hz), 140.1 (*J*_{CF} 12Hz) 153.2 (*J*_{CF} 246Hz).

(4-Azido-2-methylphenoxy)triisopropylsilane 6c. Yield 64%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.01 (18H, d, *J* 7.0, 3CH₃), 1.10-1.21 (3H, m, CH), 2.15 (3H, s, CH₃), 6.62 (1H, dd, *J* 8.5, 2.8, ArH), 6.67 (1H, dd, *J* 8.5, 6.7, ArH), 6.72 (1H, m, ArH); ¹³C NMR δ_c (75.4 MHz, CDCl₃) 12.99, 17.08, 17.99, 116.96, 118.82, 121.33, 130.27, 131.92, 151.73.

(4-Azido-3-methylphenoxy)triisopropylsilane 6d. Yield 70%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.01 (18H, d, *J* 7.3, 3CH₃), 1.10-1.21 (3H, m, 3CH), 2.08 (3H, s, CH₃), 6.61 (1H, d, *J* 2.6, ArH), 6.65 (1H, dd, *J* 8.5 and 2.6, ArH), 6.86 (1H, d, *J* 8.5, ArH); ¹³C NMR δ_c (75.4 MHz, CDCl₃) 17.95, 18.31, 19.31, 119.74, 121.84, 124.70, 134.20, 134.79, 154.80.

Triisopropylsilyl 2-azido-5-((triisopropylsilyloxy)benzoate 6e. Yield 85%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.01 (18H, d, *J* 7.3, 3CH₃), 1.05 (18H, d, *J* 7.3, 3CH₃), 1.10-1.21 (3H, m, 3CH), 1.23-1.38 (3H, m, 3CH), 6.99 (1H, dd, *J* 8.6, 2.6, ArH), 7.04 (1H, d, *J* 8.6, ArH), 7.42 (1H, d, *J* 2.6, ArH); ¹³C NMR δ_c (75.4 MHz, CDCl₃) 12.0, 12.6, 17.80, 17.82, 121.2, 123.11, 124.1, 125.2, 133.5, 152.7, 164.1.

Triisopropylsilyl 5-azido-2-((triisopropylsilyloxy)benzoate 6f. Yield 70%, oil; ¹H NMR δ_H (300 MHz; CDCl₃) 1.03 (18H, d, *J* 7.3, CH₃ iPr), 1.06 (18H, d, *J* 7.3, 6CH₃), 1.12-1.38 (6H, m, 6CH), 6.79 (1H, d, *J* 8.7, ArH), 6.90 (1H, dd, *J* 8.7 and 2.9, ArH), 7.38 (1H, d, *J* 2.9, ArH); ¹³C NMR δ_c (75.4 MHz, CDCl₃) 12.04, 13.13, 17.88, 17.98, 121.76, 122.06, 123.24, 124.62, 131.86, 153.83, 163.39.

4-((Trimethylsilyl)ethynyl)phenol. A solution of 4-iodophenol (0.880 g, 4 mmol), trimethylsilylacetylene (0.855 mL, 6 mmol), PdCl₂ (35.8 mg, 0.20 mmol, 5 mol%), Ph₃P (0.106 g, 0.40 mmol, 10 mol%), CuI (19 mg, 0.10 mmol, 2.5 mol%), and triethylamine (3.94 mL, 28.2 mmol) in of dry acetonitrile (20 mL) was heated at reflux under an argon atmosphere. After 3 h of reflux the reaction mixture was filtered through a celite pad. The filtrate was concentrated under reduced pressure and chromatographed on silica gel using a AcOEt/hexane (1:4) as eluent to afford the desired compound (0.533 g, 70%) as a brown solid; ¹H NMR δ_H (300 MHz; CDCl₃) 0.16 (9H, s, 3CH₃), 4.60-5.50 (1H, brs, OH), 6.65 (2H, d, *J* 8.7, ArH), 7.27 (2H, d, *J* 8.7, ArH); ¹³C NMR δ_c (75.4 MHz, CDCl₃) 0.15, 103.68, 106.71, 114.22, 116.85, 132.78, 158.43.

General method for the click reactions.

A solution of 4-((trimethylsilyl)ethynyl)phenol (0.1 g, 0.53 mmol) or 3-ethynylphenol (0.063 g, 0.53 mmol) and the corresponding azide (0.53 mmol) in DMF (10 mL) was treated with 1M solution of tetrabutylammonium fluoride in THF (see the

amount below for each example) under argon. The reaction mixture was stirred at 0 °C for 30 min. Then, a freshly prepared 1 M aqueous solution of sodium ascorbate (0.2 eq) was added, followed by the addition of copper (II) sulfate pentahydrate (0.1 eq). After stirring for 24 h under argon atmosphere, the reaction mixture was concentrated under vacuum. Then AcOEt (50 mL) was added and the solution was washed with 0.1 M HCl. The solvent was evaporated and the resulting residue was purified by column chromatography on silica using AcOEt/hexane as eluent, to yield the desired product.

4-(4-(4-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-3-

(trifluoromethyl)phenol 2a. From tetrabutylammonium fluoride (1.11 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 78%; mp 183-184 °C; v_{\max} (KBr)/cm⁻¹ 3500, 3037, 2917, 1619; ¹H NMR δ_{H} (300 MHz; CD₃OD) 5.08 (2H, brs, 2OH), 6.90 (2H, d, *J* 8.6, ArH), 7.18 (1H, dd, *J* 8.6, 2.6, ArH), 7.29 (1H, d, *J* 2.6, ArH), 7.43 (1H, d, *J* 8.6, ArH), 7.72 (2H, d, *J* 8.6, ArH), 8.34 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 115.0 (*J*_{CF} 5Hz), 116.9, 120.5, 122.6, 124.1 (*J*_{CF} 273Hz), 124.2, 127.06, 128.0, 128.4, 128.7 (*J*_{CF} 32Hz), 131.9, 135.1, 149.0, 159.2, 161.0. MS (ESI) *m/z*: 344.00 [M+Na]⁺, 322.04 [M+H]⁺

2-Fluoro-4-(4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl)phenol 2b. From tetrabutylammonium fluoride (1.11 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 76%, mp 258-259 °C; v_{\max} (KBr)/cm⁻¹ 3268, 3156, 2917, 1615; ¹H NMR δ_{H} (300 MHz; CD₃OD) 4.83 (2H, br s, 2OH), 6.86 (2H, d, *J* 8.6, ArH), 7.09 (1H, t, *J* 8.9, ArH), 7.47-7.53 (1H, m, ArH), 7.62 (1H, dd, *J* 11.5 and 2.5, ArH), 7.69 (2H, d, *J* 8.6, ArH), 8.59 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 110.3 (*J*_{CF} 23Hz), 116.8, 117.9 (*J*_{CF} 3Hz), 119.3 (*J*_{CF} 13Hz), 119.44, 122.8, 128.3, 130.6, 147.1 (*J*_{CF} 13Hz), 152.8 (*J*_{CF} 243Hz), 159.2. MS (ESI) *m/z*: 293.98 [M+Na]⁺, 271.99 [M+H]⁺

4-(4-(4-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-2-

methylphenol 2c. From tetrabutylammonium fluoride (1.11 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 83%, mp 242-243 °C; v_{\max} (KBr)/cm⁻¹ 3335, 3149, 2917, 1612; ¹H NMR δ_{H} (300 MHz; DMSO) 2.23 (3H, s, CH₃), 6.86 (2H, d, *J* 8.0, ArH), 6.95 (1H, d, *J* 8.5, ArH), 7.52 (1H, d, *J* 7.9, ArH), 7.62 (1H, s, ArH), 7.73 (2H, d, *J* 7.9, ArH), 8.89 (1H, s, Triazole-H), 9.60 (1H, s, OH), 9.82 (1H, s, OH); ¹³C NMR δ_{C} (75.4 MHz, DMSO) 15.9, 115.0, 115.6, 117.9, 118.7, 121.4, 122.5, 125.2, 126.6, 128.6, 147.2, 155.6, 157.3. MS (ESI) *m/z*: 268.00 [M+H]⁺

4-[4-(4-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl]-3-

methylphenol 2d. From tetrabutylammonium fluoride (1.11 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 70%, mp 203 °C; v_{\max} (KBr)/cm⁻¹ 3425, 3186, 2537, 1612; ¹H NMR δ_{H} (300 MHz; CD₃OD) 2.10 (3H, s, CH₃), 5.00 (2H, br s, 2OH), 6.77-6.83 (2H, m, ArH), 6.89 (2H, d, *J* 8.5, ArH), 7.20 (1H, d, *J* 8.5, ArH), 7.71 (2H, d, *J* 8.5, ArH), 8.25 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 17.9, 114.6, 116.9, 118.6, 122.9, 123.2, 128.4, 129.8, 136.7, 149.0, 159.1, 160.1. MS (ESI) *m/z*: 267.98 [M+H]⁺

5-Hydroxy-2-(4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl)benzoic acid 2e.

From tetrabutylammonium fluoride (1.65 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 5:1; yield 63%, 122-128 °C; v_{\max} (KBr)/cm⁻¹ 3261, 2925,

1612.08; ¹H NMR δ_{H} (300 MHz; CD₃OD) 5.00 (2H, brs, OH), 6.87 (2H, d, *J* 8.4, ArH), 7.08 (1H, dd, *J* 8.7 and 3.0, ArH), 7.38 (2H, dd *J* 8.7 and 3.0, ArH), 7.69 (2H, d, *J* 8.4, ArH), 8.34 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 116.8, 118.2, 119.6, 123.0, 123.5, 128.3, 128.9, 129.4, 148.8, 159.0, 160.2, 169.4, 175.6. MS (ESI) *m/z*: 297.98 [M+H]⁺

2-Hydroxy-5-(4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl)benzoic acid 2f.

From tetrabutylammonium fluoride (1.65 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 5:1; yield 71%, mp 272-273 °C (dec.); v_{\max} (KBr)/cm⁻¹ 3395, 3141, 2917, 2850, 1675, 1612; ¹H NMR δ_{H} (300 MHz; CD₃OD) 4.86 (2H, brs, OH), 6.89 (2H, d, *J* 8.6, ArH), 6.99 (1H, d, *J* 8.7, ArH), 7.71-7.79 (3H, m, ArH), 8.30 (1H, d, *J* 2.1, ArH), 8.58 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 117.0, 118.7, 119.2, 121.1, 123.0, 124.0, 126.2, 128.3, 129.4, 149.7, 159.3, 163.63. MS (ESI) *m/z*: 297.99 [M+H]⁺

4-(4-(3-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-3-

(trifluoromethyl)phenol 3a. From tetrabutylammonium fluoride (0.55 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 82%, mp 182-183 °C; v_{\max} (KBr)/cm⁻¹ 3261, 3194, 2925, 2589, 1612; ¹H NMR δ_{H} (300 MHz; CD₃OD) 4.94 (2H, br s, 2OH), 6.80-6.84 (1H, m, ArH), 7.16 (1H, dd, *J* 8.6, 2.8, ArH), 7.24 (1H, d, *J* 7.8, ArH), 7.29-7.37 (3H, m, ArH), 7.44 (1H, d, *J* 8.6, ArH), 8.41 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 113.7, 114.9, 116.7, 118.2, 120.5, 124.1 (*J*_{CF} 273Hz), 125.3, 127.0, 128.7 (*J*_{CF} 37Hz), 131.2, 131.9, 132.5, 148.8, 159.1, 161.0. MS (ESI) *m/z*: 344.01 [M+Na]⁺, 322.05 [M+H]⁺

2-Fluoro-4-(4-(3-hydroxyphenyl)-1H-1,2,3-triazol-1-yl)phenol

3b. From tetrabutylammonium fluoride (0.55 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 81%, mp 225-226 °C; v_{\max} (KBr)/cm⁻¹ 3305, 2925, 2850, 1615; ¹H NMR δ_{H} (300 MHz; CD₃OD) 4.85 (2H, br s, 2OH), 6.79-6.82 (1H, m, ArH), 7.09 (1H, t, *J* 8.9, ArH), 7.24 (1H, t, *J* 7.9, ArH), 7.31-7.35 (2H, m, ArH), 7.48-7.52 (1H, m, ArH), 7.64 (1H, dd, *J* 11.4 and 2.5, ArH), 8.64 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 110.2 (*J*_{CF} 23Hz), 113.6, 116.6, 118.0 (*J*_{CF} 4Hz), 118.2, 119.4 (*J*_{CF} 4Hz), 120.3, 130.4 (*J*_{CF} 8Hz), 131.1, 132.6, 147.2 (*J*_{CF} 13Hz), 149.5, 152.8 (*J*_{CF} 243Hz), 159.1. MS (ESI) *m/z*: 293.97 [M+Na]⁺, 271.97 [M+H]⁺

4-(4-(3-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-2-

methylphenol 3c. From tetrabutylammonium fluoride (0.55 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 84%, mp 196-197 °C; v_{\max} (KBr)/cm⁻¹ 3318, 3141, 2925, 2850, 1615; ¹H NMR δ_{H} (300 MHz; CD₃OD) 2.28 (3H, s, CH₃), 4.83 (2H, brs, OH), 6.78-6.82 (1H, m, ArH), 6.90 (1H, d, *J* 8.6, ArH), 7.25 (1H, t, *J* 7.9), 7.32-7.35 (3H, m, ArH), 7.47 (1H, dd, *J* 8.6 and 2.6), 7.55 (1H, d, *J* 2.5, ArH), 8.59 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 16.3, 113.6, 116.1, 116.5, 118.2, 120.4, 120.5, 124.3, 127.4, 130.5, 131.1, 132.8, 149.3, 157.6, 159.1. MS (ESI) *m/z*: 268.00 [M+H]⁺

4-(4-(3-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-3-

methylphenol 3d. From tetrabutylammonium fluoride (0.55 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 3:2; yield 80%, mp 210-211 °C; v_{\max} (KBr)/cm⁻¹ 3291, 2440, 1615; ¹H NMR δ_{H} (300 MHz; CD₃OD) 2.12 (3H, s, CH₃), 4.83 (2H, br s, 2OH), 6.76-6.83 (3H, m, ArH), 7.21-7.35 (4H, m, ArH), 8.35 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD)

17.8, 113.6, 114.6, 116.5, 118.2, 118.6, 124.3, 128.5, 129.8, 131.2, 132.8, 136.7, 148.8, 159.2, 160.2. MS (ESI) m/z : 289.98 [M+Na]⁺, 267.98 [M+H]⁺

5-Hydroxy-2-(4-(3-hydroxyphenyl)-1H-1,2,3-triazol-1-

yl)benzoic acid 3e. From tetrabutylammonium fluoride (1.11 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 5:1; yield 71%, mp 165-166 °C; ν_{\max} (KBr)/cm⁻¹ 3313, 2917, 1705, 1589; ¹H NMR δ_{H} (300 MHz; DMSO) 6.73-6.76 (1H, m, ArH), 7.10 (1H, dd, J 8.6 and 2.8), 7.22-7.35 (4H, m, ArH), 7.44 (1H, d, J 8.5, ArH), 8.77 (1H, s, Triazole-H), 9.54 (1H, brs, OH), 10.38 (1H, brs, OH), 12.92 (1H, brs, COOH); ¹³C NMR δ_{C} (75.4 MHz, DMSO) 111.8, 114.8, 116.0, 116.6, 118.6, 123.1, 127.1, 128.3, 129.7, 129.8, 131.8, 146.0, 157.7, 158.3, 166.1. MS (ESI) m/z : 297.98 [M+H]⁺

2-Hydroxy-5-(4-(3-hydroxyphenyl)-1H-1,2,3-triazol-1-

yl)benzoic acid 3f. From tetrabutylammonium fluoride (1.11 mL, 1M solution in THF); chromatography eluent: AcOEt/Hexane 5:1; yield 68%, mp 243-244 °C with decomposition; ν_{\max} (KBr)/cm⁻¹ 3134, 2917, 1675, 1619; ¹H NMR δ_{H} (300 MHz; DMSO) 6.78 (1H, d, J 7.7, ArH), 7.20 (1H, d, J 8.9, ArH), 7.27 (1H, t, J 7.9, ArH), 7.34-7.39 (2H, m, ArH), 8.07 (1H, dd, J 8.9 and 2.6, ArH), 8.29 (1H, d, J 2.6, ArH), 9.23 (1H, s, Triazole-H), 9.57 (1H, brs, OH); ¹³C NMR δ_{C} (75.4 MHz, DMSO) 112.0, 113.9, 115.1, 116.2, 118.5, 119.5, 121.5, 127.2, 128.5, 129.9, 131.4, 147.2, 157.7, 160.7, 170.8. MS (ESI) m/z : 297.99 [M+H]⁺

General Method for the synthesis of methyl esters 2g,h and 3h.

The corresponding acid (**2e**, **2f**, or **3f**) (0.17 mmol) was dissolved in MeOH (10 mL) and few drops of sulfuric acid were added. The reaction mixture was heated under reflux for 6 hours in argon atmosphere. Then the reaction mixture was concentrated under vacuum and the resulting residue was purified by column chromatography on silica eluting using AcOEt/DCM (3:1) as eluent to yield the desired product.

Methyl 5-hydroxy-2-(4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-

yl)benzoate 2g. Yield 73%, mp 224-225 °C; ν_{\max} (KBr)/cm⁻¹ 3373, 3059, 2925, 1723, 1686, 1619; ¹H NMR δ_{H} (300 MHz; CD₃OD) 3.74 (3H, s, OCH₃), 6.00 (2H, brs, OH), 6.97 (2H, d, J 8.7, ArH), 7.21 (1H, dd, J 8.7 and 2.7, ArH), 7.51 (1H, d, J 2.6 ArH), 7.62 (1H, d, J 8.7, ArH), 7.74 (2H, d, J 8.7, ArH), 9.01 (1H, s, Triazole-H); ¹³C NMR δ_{C} (75.4 MHz, CD₃OD) 53.4, 115.8, 117.7, 119.3, 121.0, 127.4, 127.6, 129.2, 129.7, 130.3, 144.8, 161.7, 161.9, 165.6. MS (ESI) m/z : 312.03 [M+H]⁺

Methyl 2-hydroxy-5-(4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-

yl)benzoate 2h. Yield 86%, mp 211-213 °C; ν_{\max} (KBr)/cm⁻¹ 3261, 3141, 2955, 2925, 1679, 1619; ¹H NMR δ_{H} (300 MHz; DMSO) 3.95 (3H, s, CH₃), 6.88 (2H, d, J 8.4, ArH), 7.23 (1H, d, J 8.4, ArH), 7.75 (2H, d, J 8.6, ArH), 8.05 (1H, dd, J 8.9 and 2.8, ArH), 8.25 (1H, d, J 2.8, ArH), 9.08 (1H, s, Triazole-H), 9.68 (1H, br s, OH), 10.60 (1H, br s, OH); ¹³C NMR δ_{C} (75.4 MHz, DMSO) 52.6, 114.3, 115.6, 118.8, 121.2, 121.3, 126.7, 126.9, 128.8, 147.5, 157.5, 159.2, 167.8. MS (ESI) m/z : 312.03 [M+H]⁺

Methyl 2-hydroxy-5-(4-(3-hydroxyphenyl)-1H-1,2,3-triazol-1-

yl)benzoate 3h. Yield 72%, mp 202-203 °C; ν_{\max} (KBr)/cm⁻¹ 3141, 2955, 1671, 1612; ¹H NMR δ_{H} (300 MHz; DMSO) 3.95 (3H, s, CH₃), 6.76-6.80 (1H, m, ArH), 7.25 (2H, t, J 8.9, ArH), 7.30-7.39 (2H, m, ArH), 8.07 (1H, dd, J 8.9, 2.8, ArH), 8.27 (1H,

d, J 2.8, ArH), 9.21 (1H, s, Triazole-H), 9.59 (1H, br s, OH), 10.69 (1H, br s, OH); ¹³C NMR δ_{C} (75.4 MHz, DMSO) 52.6, 112.0, 114.3, 115.1, 116.2, 118.8, 119.5, 121.4, 127.0, 128.7, 129.9, 131.4, 147.3, 157.7, 159.2, 167.7. MS (ESI) m/z : 312.02 [M+H]⁺

Computational methods.

To perform the theoretical study of the binding mode both subtypes of ER α and ER β , have been taken into account. As macromolecules, several crystallographic structures of the two receptor subtypes in complex with several ligands have been considered: ER α in complex with estradiol (PDB 1A52), raloxifene (PDB 1ERR), genistein (PDB 1X7R), WAY-244 (PDB 1X7E), and 4-hydroxytamoxifen (PDB 3ERT), and ER β in complex with genistein (PDB 1X7J), THC (PDB 1L2J), WAY-202196 (PDB 1YYE), and 4-hydroxytamoxifen (PDB 2FSZ). Water molecules close to the amino acids Arg394 (ER β Arg346) and Glu353 (Glu305 ER β) were kept for the docking procedures. Eleven ligands (compounds **2a-2g** and **3a-3f**) were built using Maestro LigPrep module (www.schrodinger.com). Gaussian 03¹⁶ at B3LYP/3-21G* level was used to optimize the geometries and to calculate point charges. Atom types and bond types were assigned, and mol2 files were generated. Macromolecule geometries were refined by using Protein Preparation module in Maestro. The Glide module was used to perform the docking calculations.^{17, 18} The center of the box was positioned on the center of the bound ligand present in the crystallographic structure, and box size was set up to enclose the ligand binding domain. The docking procedure was performed with XP (extra precision) mode, and a van der Waals radii scale factor of 1.0/0.8 for receptor and ligand, respectively. Induced Fit Docking was also used, and contained constrained minimization of the receptor with an RMSD cutoff of 0.18 Å, and Prime-side-chain prediction on residues within a 5 Å of any ligand pose. Glide redocking was performed into structures within 30 kcal mol⁻¹ of the lowest energy structure with van der Waals scaling of 1.0/0.8 for receptor and ligand, respectively. The best obtained result for each ligand was considered for analysis of the ligand-receptor interactions.

Biological Assays

Chemicals. 17- β -estradiol, crystal violet, dextran coated charcoal, PSB, Tween-20, BSA, insulin were purchased from Aldrich. Estradiol [2,4,6,7,16,17-³H(N)], scintillation counting liquid (Optifase HiSafe2) were obtained from Perkin-Elmer, Salem, MA). Estrogen receptors α and β produced in insect cells and sodium pyruvate were purchased from Invitrogen. Cell culture medium DMEM, FBS, antibiotics, trypsin-EDTA, amino acids, L-glutamine were purchased from Lonza. DCC-FBS was obtained from Hyclone (Erembodegem, Aalst, Belgium) and DMEM without phenol red from Gibco.

Receptor Binding Studies. The ability of the compounds to bind to ERs has been determined by competition assay according to method of Arcaro with some modifications (1). Purified full-length human ER α and ER β have been incubated for 4 hr at 23°C with different concentrations of compounds in the presence of 5 nM [2,4,6,7,16,17-³H]-estradiol in total volume 150 μ l. The stock

of tested compounds has been prepared in DMSO. All these compounds, including [2,4,6,7,16,17-3H]-estradiol and receptors were diluted in Tween/PBS buffer (99,85:0,15 w/v). A vehicle control contained 0,1% of DMSO. After incubation the non-bound [2,4,6,7,16,17-3H]-estradiol has been removed by adding mixture of 10% DCC and 2% albumin bovin serum, incubating 15 min at 4°C, followed by centrifugation at 6000g for 5 min at 4°C. 150 µl of supernatant was added to 4 mL of scintillation liquid and the bound estradiol was measured in liquid scintillation counter Beckman LS 6500 (Beckman Coulter, Inc.). Two independent experiments with three repetitions for each compound were performed. Results were expressed as the percentage of specific binding of [2,4,6,7,16,17-3H]-estradiol to ER versus log of competitor concentration. Graph Pad Prism software (non-linear regression analysis) was used to calculate the concentration needed to displace 50% of [2,4,6,7,16,17-3H]-estradiol (IC₅₀). The values of IC₅₀ for estradiol were 8.98 and 6.87 nM for ERα and ERβ, respectively.

Proliferation assay. MCF-7 cells were seeded in 96-well plates at 5*10³ cells/well in DMEM containing 10% FBS, 0,01mg/ml insulin solution, 0,1 mM nonessential amino acids. After 24 hours medium was changed for DMEM without phenol red, containing 5% dextran-coated charcoal stripped FBS (DCC-FBS), 0,1 mM nonessential amino acids, 1mM sodium pyruvate and 2mM L-glutamine and preincubated 3 days prior to treatment. Afterwards different concentrations of assayed compounds (1-50 µM) were added to cells with/without 1pM estradiol in order to test the capacity to induce or prevent the proliferation of MCF-7 cells. The final vehicle concentration maximally 0,1% of DMSO (and 0,1% of ethanol in case of treatment with estradiol) served as a solvent control. On day 4 medium with compounds was refreshed. On day 8 the media were removed and cells were fixed and stained with a solution containing 1% ethanol and 0.5% crystal violet. After rinsing and drying, the dye was solubilized with 1% SDS and the absorbance was read at 570 nm (Biotec). The viability was calculated considering controls without test substance as 100% viable.

Agonist Profile. The agonistic and antagonistic activities of compounds were evaluated using a commercially available cell-based assay (INDIGO Bioscience's ER Reporter Assay), which allows to quantify functional activities of the test compounds, against ERα and ERβ. The system utilizes non-human mammalian cells engineered to provide constitutive high-level expression of ERα and ERβ. Additionally, these cells contain either ERα or ERβ-responsive luciferase reporter gene. Thus, quantification of luciferase activity provides a surrogate measure of ERα and ERβ activity in the treated reporter cells. Reporter cells were dispensed in 96-well plate and then immediately dosed

Notes

^a Departamento de Química, Facultad de Farmacia, Universidad CEU San Pablo, 28668-Boadilla del Monte, Madrid, Spain.

E-mail: aramgon@ceu.es, bpaster@ceu.es; Fax: (+34)913510496; Tel: (+34)913724796;

^b Department of Organic Chemistry, Gdansk University of Technology, 11/12 G. Narutowicza St., 80-233 Gdańsk, Poland.

with the test compounds. Following overnight incubation, the treatment media were discarded and luciferase detection reagent was added. The intensity of light emission from the ensuing luciferase reaction provides a measure that is directly proportional to the level of ER activation in the reporter cells. The assays were configured to perform agonist and antagonist dose-response curves. In order to obtain agonist dose-response curves ER reporter cells were treated with media alone. Estradiol was used as a positive control agonist. The EC₅₀ values of estradiol for ERα and ERβ were 330 and 77 pM, respectively. The highest concentrations of estradiol used in order to ensure the saturating conditions were 100nM (ERα) and 4nM (ERβ). The final solvent control didn't exceed 0,1% of DMSO. All measurements were performed in triplicate.

Abbreviations

| | |
|-------------------|--|
| DCM | dichloromethane |
| THF | tetrahydrofuran |
| DMF | dimethylformamide |
| RT | room temperature |
| ER | estrogen receptor |
| CuACC | copper-catalyzed reaction between an azide and an alkyne |
| TLC | thin layer chromatography |
| TIPSCl | triisopropylsilyl chloride |
| TMSN ₃ | azidotrimethylsilane |
| CNS | central nervous system |
| TFA | trifluoroacetic acid |
| EDTA | ethylenediaminetetraacetic acid |
| DCC-FBS | dextran-coated charcoal-stripped fetal bovine serum |

Acknowledgements

This work was supported by the Spanish Ministry of Science and Innovation (SAF2008-00945, CTQ2011-24741 and AGL2012-30803) and Fundación Universitaria San Pablo CEU (USP-PC 13/10 and 15/11). We thank EADS-CASA for fellowships to K. F., M. M., J. C. and S. D.

^c Department of Molecular Biology, Faculty of Mathematics and Natural Sciences, The John Paul II Catholic University of Lublin, 20-718 Lublin, Poland.

^d Department of Environmental Biochemistry and Chemistry, Faculty of Mathematics and Natural Sciences, The John Paul II Catholic University of Lublin, 20-718 Lublin, Poland.

^e Institute of Food Science, Food Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), José Antonio Novais 10, 28040-Madrid, Spain.

† Electronic Supplementary Information (ESI) available: NMR spectra of compounds **2a-2h**, **3a-3f** and **3h**. Predicted binding energies from the docking studies

Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez and J. A. Pople; Wallingford CT, 2004.
17. R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, D. E. Shaw, M. Shelley, J. K. Perry, P. Francis and P. S. Shenkin, *J. Med. Chem.*, 2004, 47, 1739–1749.
18. T. A. Halgren, R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Frye, W. T. Pollard and J. L. Banks, *J. Med. Chem.*, 2004, 47, 1750–1759.

References

1. J. A. Gustafsson, *J. Endocrinol.*, 1999, 163, 379–383.
2. R. E. Mewshaw, J. Edsall, Richard J., C. Yang, E. S. Manas, Z. B. Xu, R. A. Henderson, J. C. Keith Jr. and H. A. Harris, *J. Med. Chem.*, 2005, 48, 3953–3979.
3. H. A. Harris, L. M. Albert, Y. Leathurby, M. S. Malamas, R. E. Mewshaw, C. P. Miller, Y. P. Kharode, J. Marzolf, B. S. Komm, R. C. Winneker, D. E. Frail, R. A. Henderson, Y. Zhu and J. C. Keith, *Endocrinology*, 2003, 144, 4241–4249.
4. M. J. Meyers, J. Sun, K. E. Carlson, G. A. Marriner, B. S. Katzenellenbogen and J. A. Katzenellenbogen, *J. Med. Chem.*, 2001, 44, 4230–4251.
5. E. S. Manas, R. J. Unwalla, Z. B. Xu, M. S. Malamas, C. P. Miller, H. A. Harris, C. Hsiao, T. Akopian, W.-T. Hum, K. Malakian, S. Wolfrom, A. Bapat, R. A. Bhat, M. L. Stahl, W. S. Somers and J. C. Alvarez, *J. Am. Chem. Soc.*, 2004, 126, 15106–15119.
6. M. De Angelis, F. Stossi, K. A. Carlson, B. S. Katzenellenbogen and J. A. Katzenellenbogen, *J. Med. Chem.*, 2005, 48, 1132–1144.
7. S. Martin-Santamaria, J. J. Rodriguez, S. de Pascual-Teresa, S. Gordon, M. Bengtsson, I. Garrido-Laguna, B. Rubio-Viqueira, P. P. López-Casas, M. Hidalgo, B. de Pascual-Teresa and A. Ramos, *Org. Biomol. Chem.*, 2008, 6, 3486–3496.
8. *Spain Pat*, ES P200801961; 2008.
9. J. J. Rodriguez, K. Filipiak, M. Maslyk, J. Ciepielski, S. Demkowicz, S. de Pascual-Teresa, S. Martin-Santamaria, B. de Pascual-Teresa and A. Ramos, *Org. Biomol. Chem.*, 2012, 10, 7334–7346.
10. G. C. Tron, T. Pirali, R. A. Billington, P. L. Canonico, G. Sorba and A. A. Genazzani, *Med. Res. Rev.*, 2008, 28, 278–308.
11. S. K. Mamidyala and M. G. Finn, *Chem. Soc. Rev.*, 2010, 39, 1252–1261.
12. T. Pirali, S. Gatti, R. Di Brisco, S. Tacchi, R. Zaninetti, E. Brunelli, A. Massarotti, G. Sorba, P. L. Canonico, L. Moro, A. A. Genazzani, G. C. Tron and R. A. Billington, *Chemmedchem*, 2007, 2, 437–440.
13. K. F. Arcaro, Y. Yang, D. D. Vakharia and J. F. Gierthy, *Journal of Toxicology and Environmental Health-Part A*, 2000, 59, 197–210.
14. F. Minutolo, M. Macchia, B. S. Katzenellenbogen and J. A. Katzenellenbogen, *Med. Res. Rev.*, 2011, 31, 364–442.
15. J. A. Katzenellenbogen, B. W. Omalley and B. S. Katzenellenbogen, *Mol. Endocrinol.*, 1996, 10, 119–131.
16. Gaussian 03, Revision C.02, Gaussian, Inc., M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. Montgomery, J. A., T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W.